Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference
10 Agosto 2023 - 5:15PM
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the
“Company”), a clinical-stage pharmaceutical company now focused on
developing the next generation of chemotherapeutic drugs to improve
the efficacy and safety for patients suffering from cancer,
announces that David Young, President of Research and Development,
will present a corporate overview at the Sidoti & Co. Micro Cap
Virtual Conference being held on August 16 – 17, 2023.
Presentation Date: August 17, 2023
Time: 11:30am ET
Webcast
Link:https://sidoti.zoom.us/webinar/register/WN_gNKc8VQySWKLfKU7bkjdkg
In addition, George Ng, Processa’s
recently-appointed Chief Executive Officer, and David Young will be
available for one-on-one meetings throughout the conference.
Investors can attend the conference and request a meeting with
management by registering for the conference using the link
below:
Registration: https://www.sidoti.com/events
About Processa Pharmaceuticals,
Inc.
Processa is a clinical stage pharmaceutical
company focused on developing the Next Generation Chemotherapy
drugs to improve the safety and efficacy of cancer treatment. By
combining Processa’s novel oncology pipeline with proven
cancer-killing active molecules and the Processa Regulatory Science
Approach as well as experience in defining Optimal Dosage Regimens
for FDA approvals, Processa not only will be providing better
therapy options to cancer patients but also increase the
probability of FDA approval for its Next Generation Chemotherapy
drugs. Processa’s NGC drugs are modifications of existing
FDA-approved oncology drugs resulting in an alteration of the
metabolism and/or distribution of drugs while maintaining the
existing mechanisms of killing the cancer cells. Our approach to
drug development is based on more than 30 years of drug development
expertise to efficiently design and conduct clinical trials that
demonstrate a positive benefit/risk relationship. Using its proven
Regulatory Science Approach, we have experience defining the
Optimal Dosage Regimen using the principles of the FDA’s Project
Optimus Oncology initiative. The advantages of Processa’s Next
Generation Chemotherapy drugs are expected to include fewer
patients experiencing side effects that lead to dose
discontinuation; more significant cancer response; and a greater
number of patients who will benefit from each Next Generation
Chemotherapy drug. Currently in our pipeline are three Next
Generation Chemotherapy drugs: Next Generation Capecitabine
(PCS6422 and capecitabine to treat metastatic colorectal,
gastrointestinal, breast, pancreatic, and other cancers), Next
Generation Gemcitabine (PCS3117 to treat pancreatic, lung, ovarian,
breast, and other cancers), and Next Generation Irinotecan (PCS11T
to treat lung, colorectal, gastrointestinal, pancreatic, and other
cancers).
For more information, visit our website at
www.processapharma.com.
Forward-Looking Statements
This release contains forward-looking
statements. The statements in this press release that are not
purely historical are forward-looking statements which involve
risks and uncertainties. Actual future performance outcomes and
results may differ materially from those expressed in
forward-looking statements. Please refer to the documents filed by
Processa Pharmaceuticals with the SEC, specifically the most recent
reports on Forms 10-K and 10-Q, which identify important risk
factors which could cause actual results to differ from those
contained in the forward-looking statements.
For More
Information:Investors:Bret ShapiroCORE
IRir@processapharma.com
Company Contact:Patrick Lin(925)
683-3218plin@processapharma.com
Processa Pharmaceuticals (NASDAQ:PCSA)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Processa Pharmaceuticals (NASDAQ:PCSA)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024